Literature DB >> 3092407

Carbamazepine drug interactions.

A M Baciewicz.   

Abstract

Carbamazepine (CBZ) is commonly prescribed as an anticonvulsant or for the pain of trigeminal neuralgia. The potential for clinically important drug interactions exists because CBZ may induce the hepatic metabolism of other drugs or, conversely, other drugs may induce or inhibit the metabolism of CBZ. Studies and case reports demonstrate that CBZ may accelerate the metabolism of phenytoin, phenobarbital (PB), primidone, valproic acid, and warfarin. Likewise, phenytoin, PB, and primidone may increase the hepatic metabolism of CBZ. Inhibition of the metabolism of CBZ has been caused by triacetyloleandomycin, erythromycin, propoxyphene, isoniazid, and cimetidine. Future investigations will document the clinical significance of the CBZ interactions as well as reveal new interactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092407     DOI: 10.1097/00007691-198609000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  20 in total

1.  Severe hepatorenal failure in a child receiving carbamazepine and erythromycin.

Authors:  F Viani; A Claris-Appiani; L N Rossi; M Giani; A Romeo
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

Review 2.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 3.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 4.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

6.  Carbamazepine and its metabolites in neuralgias: concentration-effect relations.

Authors:  R S Moosa; M L McFadyen; R Miller; J Rubin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.

Authors:  M Marchand; E Fuseau; D J Critchley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-02       Impact factor: 2.745

Review 8.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

9.  Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.

Authors:  P J McKee; J Blacklaw; E Butler; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 10.  Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.

Authors:  S M Grant; D Faulds
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.